Validating Pan-TRK IHC may otherwise bridge this gap or delay in NTRK testing, especially if pan-TRK IHC is employed at the time of pathologic evaluation of advanced or metastatic cancers. Here, TPM3 is linked to metastatic malignant neoplasm.